GCV Asia Congress 2018
Skip Content

11 July 2018

Antiva enters series C1 stage with $15m

EMS subsidiary Brace Pharma Capital returned to help HPV therapy developer Antiva Biosciences increase its overall funding to $57m.

Author: Thierry Heles, editor, Global University Venturing

Antiva Biosciences, a US-based human papilloma virus (HPV) therapy developer, raised $15m yesterday in a series C1 round featuring Brace Pharma Capital, the investment arm of pharmaceutical firm EMS.